|Dr Geoff Coxon|
Dr Geoff Coxon obtained out his PhD research under the supervision of Prof David Minnikin at the University of Newcastle upon Tyne in 1999. The research was carried out in close collaboration with Prof Patrick Brennan and then, Dr Gurdyal Besra, involving the inhibition of mycolic acid biosynthesis. Post-dosctoral work was carried out in this field before entering project management with Procter & Gamble both in the UK and US. Returning to Newcastle University, further post-dosctoral research was undertaken with Profs Minnikin and Besra before moving to the University of Strathclyde. After working initially at the Dept of Pure & Applied Chemistry, working with Prof David Sherrington, Dr Coxon moved to the Strathclyde Institute of Pharmacy and Biomedical Sciences. In this role he designed and optimised compounds for the treatment of obesity, both in vitro and in vivo, which are now subject to licensing discussions with industry to further develop these towards the clinic.
In December 2004 Dr Coxon was appointed lecturer in Medicinal Chemistry SIPBS where he began establishing his research group focused on anti TB drug discovery. This work has been based on the inhibition of mycolic acid biosynthesis and has included the development of isoxyl, thiacetazone and recently, in a program to find mimics of thiolactomycin (TLM), has culminated in the discovery of the 2-aminothiazolecarboxylate scaffold as a new class of anti TB agent. These efforts have been in close collaboration with Prof Gurdyal Besra (Birmingham), Prof Stephen Gillespie and Dr Tim McHugh (UCL) and his research collaborators at SIPBS (Prof Simon Mackay, Dr Blair Johnston, Dr Nahoum Anthony, Dr Paul Hoskisson, Dr Paul Herron and Dr Veronique Seidel) as well as Prof Alan Harvey, and partners, from Strathclyde Innovations in Drug Research.
During 2007 Dr Coxon and colleagues embarked on the establishment of a UK consortium to bring together scientists involved in TB drug discovery. Following his discussions with local MP the Rt Hon Des Browne and correspondence with government ministers and advisors to foster such program, a year later, TBD-UK was established and subsequent funding obtained from the MRC to develop the program and consolidate UK research. As part of TBD-UK, Dr Coxon has taken ownership and development of www.TBD-UK.org.uk and as deputy leader and director of medicinal chemistry is committed to the discovery of new TB drugs.
1.International Development Committee-Fourteenth Report. Department for International development Annual Report and Resource Accounts 2010-11 and Business Plan 2011-15. Geoff Coxon, http://www.publications.parliament.uk/pa/cm201012/cmselect/cmintdev/1569/1569vw03.htm, 2012.
2. Coxon Geoffrey D., Cooper Christoper B., Gillespie Stephen H., McHugh Timothy D. Strategies and challenges involved in the discovry of new chemical entities during early-stage tuberculosis drug discovery. Journal of Infectious Diseases 2012; doi: 10.1093/infdis/jis191
3.Giacomo Berretta, Geoffrey D. Coxon, Synthesis of cis,cis-diunsaturated ?-meromycolic acid by a palladium-catalysed alkyl–alkyl Negishi reaction, Tet. Lett, 53, 2012, 214-216
4.Lynn G. Dover and Geoffrey D. Coxon. Currrent Status and Research Strategies in Tuberculosis Drug Development; J. Med. Chem., 2011, 54 (18), 6157–6165
5.Geoffrey D. Coxon and Stephen H. Gillespie. TB- Strength in numbers. Microbiology Today, Feburary 2010
6. Coxon, G, R.D. Waith, B. F. Furman, A.Harvey PCT/GB2009/000064 Weight Reducing Compounds (Tech1660), Patent Application, (2009).
7. Al-Balas Q, Anthony NG, Al-Jaidi B, Alnimr A, Abbott G, Brown AK, Taylor RC, Besra GS, McHugh TD, Gillespie SH, Johnston BF, Mackay SP, Coxon GD. Identification of 2-aminothiazole-4-carboxylate derivatives active against Mycobacterium tuberculosis H37Rv and the beta-ketoacyl-ACP synthase mtFabH. PLoS One. 2009;4(5):e5617.